2018-11-02T09:31:38-05:00 2017-12-31 521073331 DEMBO JONES PC 6010 EXECUTIVE BLVD SUITE 900 ROCKVILLE MD 20852 990 2017-01-01 300283980 DINORA INC DINO 2022447422 3119 51ST PL NW WASHINGTON DC 200162639 VALORIE THOMPSON PRESIDENT 2022447422 2018-11-01 1 CHERYL D FINKELSTEIN CPA P01439227 3017705100 2018-11-01 108.56.64.202 2018-11-01 14:28:04 ED P 53289E0D652D6EE9F2ACEDA51DA4AD534CB43B54 53289E0D652D6EE9F2ACEDA51DA4AD534CB43B54 2017 2019-02-21 02:37:17Z VALORIE THOMPSON 3119 51ST PLACE NW WASHINGTON DC 20016 730770 0 X N/A X 2004 DC TO SUPPORT CHARITABLE AND EDUCATIONAL ACTIVITIES THAT PROMOTE THE CLINICAL APPLICATION OF UNIQUE THEORIES AND THERAPIES TO TREAT, PREVENT AND CURE ARTHRITIS THROUGH FUNDING STUDIES, EDUCATIONAL SEMINARS & MEDICAL PUBLICATIONS THAT PROMOTE NEW THERAPIES & TREATMENT 2 1 0 0 0 0 112000 0 950358 730715 66 55 0 0 1062424 730770 237000 0 0 0 0 0 0 0 0 1064077 489032 1301077 489032 -238653 241738 498657 740395 1084 1084 497573 739311 X TO SUPPORT CHARITABLE AND EDUCATIONAL ACTIVITIES THAT PROMOTE THE CLINICAL APPLICATION OF UNIQUE THEORIES AND THERAPIES TO TREAT, PREVENT AND CURE ARTHRITIS THROUGH FUNDING STUDIES EDUCATIONAL SEMINARS AND MEDICAL PUBLICATIONS THAT PROMOTE NEW THERAPIES AND TREATMENT 0 0 96866 165000 PMR INVESTIGATOR INITIATED STUDY PROVIDES LOGISTICS AND OPERATIONS FOR A RANDOMIZED OPEN LABEL DOSE RANGING STUDY OF ORAL DELAYED RELEASE PREDNISONE IN PATIENTS WITH UNTREATED PMR. 150000 150000 ACTTION IS A PUBLIC PRIVATE PARTNERSHIP WITH THE FDA WHOSE MISSION IS TO IDENTIFY, PRIORITIZE, SPONSOR, COORDINATE, AND PROMOTE INNOVATIVE ACTIVITIES WITH A SPECIAL INTEREST IN OPTIMIZING CLINICAL TRIALS THAT WILL EXPEDITE THE DISCOVERY AND DEVELOPMENT OF IMPROVED ANALGESIC, ANESTHETIC, ADDICTION, AND PERIPHERAL NEUROPATHY TREATMENTS FOR THE BENEFIT OF THE PUBLIC HEALTH. DINORA COLLABORATES WITH ACTTION FOR FUNDRAISING. 213000 208500 OMERACT, THROUGH A DATA DRIVEN MULTI-STAKEHOLDER CONSENSUS PROCESS, STRIVES TO IDENTIFY AND IMPROVE RELEVANT HEALTH OUTCOME DOMAINS, ENDORSING VALID, RESPONSIVE, FEASIBLE HEALTH OUTCOME MEASURES IN PATIENTS WITH MUSCULOSKELETAL CONDITIONS. DINORA, AS A US BASED NONPROFIT, COLLABORATES WITH OMERACT, A CANADIAN NONPROFIT FOR FUNDRAISING, PROCUREMENT OF EDUCATIONAL GRANTS AND RESEARCH RELATED TO OUTCOME MEASUREMENT ACROSS THE SPECTRUM OF RHEUMATOLOGY INTERVENTION STUDIES. 15000 ALLIANCE FOR LUPUS RESEARCH (ALR), PROVIDES RESOURCES THROUGH THE PATIENT ADVOCATES FOR LUPUS TO THE ALR'S LUPUS CLINICAL TRIALS NETWORK LOOKING TO FURTHER DEVELOP THE RESEARCH ON LUPUS. 10889 174084 ADVANCES IN THE MANAGEMENT OF CHRONIC GOUT; EXPERT ONLINE DISCUSSION PROVIDING INFORMATION ON MECHANISMS BEHIND THE PATHOGENESIS OF GOUT AND STRATEGIES FOR OPTIMAL MANAGEMENT OF GOUT PATIENTS. 3131 FUNDING TO OVERSEE A SYSTEMATIC LITERATURE REVIEW OF IMAGING AND OSTEOARTHRITIS 30000 ANNUAL DINNER FOR INTERNATIONL RHEUMATOLOGY KEY OPINION LEADERS FOR THE PURPOSE OF REVIEWING CURRENT RESEARCH. 25889 207215 485755 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 X 2 1 0 0 0 0 0 0 0 1 0 0 0 1 1 1 1 0 1 0 0 0 X THE ORGANIZATION 2022447422 3119 51ST PL NW WASHINGTON DC 200162639 X VALORIE THOMPSON DIRECTOR 1.00 X X 0 0 0 ANTHONY A SARIDAKIS SECRETARY/TREASURER 1.00 X X 0 0 0 0 0 0 0 0 0 0 UNIVERSITY OF ROCHESTER 601 ELMWOOD AVE ROCHESTER NY 14642 CLINICAL RESEARCH 150000 1 OMERACT 541900 208500 208500 CLEVELAND CLINICAL 541900 174084 174084 PMR STUDY 541900 165000 165000 ACTTION 541900 150000 150000 INTERNATIONAL RHEUMATO 541900 30000 30000 3131 3131 730715 55 55 730770 730715 0 55 1875 1875 80 80 1282 1282 1305 1305 OMERACT EXPENSE 213000 213000 CLINCAL RESEARCH - ACTT 150000 150000 CLINCAL RESEARCH - PMR 60524 60524 DATA MANAGEMENT - PMR 18152 18152 42814 42797 17 489032 485755 3277 0 498657 740395 498657 740395 1084 1084 1084 1084 X 497573 739311 497573 739311 498657 740395 241738 0 X 0 0 0 X 233635 166500 188000 112000 0 700135 233635 166500 188000 112000 700135 277093 423042 22 26 34 66 55 203 700338 0.60410 0.59720 X NORTH AMERICA - CANADA AND MEXICO 0 0 DINORA AND OMERACT HAVE ENTERED INTO A COLLABORATIVE RELATIONSHIP TO SUPPORT THEIR OVERALL WORK IN I DINORA AND OMERACT HAVE ENTERED INTO A COLLABORATIVE RELATIONSHIP TO SUPPORT THEIR OVERALL WORK IN IMPROVING OUTCOME MEASURES IN RHEUMATOLOGY AS WELL AS THE ACTIVITIES OF OMERACT'S INDIVIDUAL WORKING GROUPS, SPECIFICALLY, DINORA, PROVIDES THE OPPORTUNITY FOR DONORS TO PROVIDE FUNDING TO THE OMERACT INITIATIVE THROUGH A US BASED TAX-EXEMPT ORGANIZATION 213000 0 0 0 0 0 0 213000 0 213000 0 0 0 0 0 0 VALORIE THOMPSON DIRECTOR OF DINORA INNOVATIONS CONSULTING GROUP PROVIDES SERVICES TO DINORA. X 1084 1084 0 1 0 1084 VALORIE THOMPSON THE DIRECTOR OF DINORA IS THE PRINCIPAL OF INNOVATIONS CONSULTING GROUP INNOVATIONS CONSULTING GROUP PROVIDES SERVICES TO DINORA, INC AND DINORA, INC REIMBURSES INNOVATIONS CONSULTING GROUP FOR COSTS INCURRED PLANNING AND PROVIDING LOGISTICAL MEETING SUPPORT. 0 FORM 990, PART VI, SECTION A, LINE 8B DINORA HAS NO COMMITTEES. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS REVIEWED BY THE BOARD ELECTRONICALLY BEFORE IT IS FILED. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST POLICY FOR PURPOSES OF THIS PROVISION, THE TERM "INTEREST" SHALL INCLUDE PERSONAL INTEREST, INTEREST AS DIRECTOR, OFFICER, TRUSTEE OR BENEFICIARY OF ANY CONCERN AND HAVING AN IMMEDIATE FAMILY MEMBER WHO HOLDS SUCH AN INTEREST IN ANY CONCERN. THE TERM "CONCERN" SHALL MEAN ANY CORPORATION, ASSOCIATION, TRUST, PARTNERSHIP, LIMITED LIABILITY ENTITY, FIRM, PERSON OR OTHER ENTITY OTHER THAN THE ORGANIZATION. NO DIRECTOR OR OFFICER OF THE ORGANIZATION SHALL BE DISQUALIFIED FROM HOLDING ANY OFFICE IN THE ORGANIZATION BY REASON OF ANY INTEREST IN ANY CONCERN. A DIRECTOR OR OFFICER OF THE ORGANIZATION SHALL NOT BE DISQUALIFIED FROM DEALING, EITHER AS VENDOR, PURCHASER OR OTHERWISE, OR CONTRACTING OR ENTERING INTO ANY OTHER TRANSACTION WITH THE ORGANIZATION OR WITH ANY ENTITY OF WHICH THE ORGANIZATION IS AN AFFILIATE NO TRANSACTION OF THE ORGANIZATION SHALL BE VOIDABLE BY REASON OF THE FACT THAT ANY DIRECTOR OR OFFICER OF THE ORGANIZATION HAS AN INTEREST IN THE CONCERN WITH WHICH SUCH TRANSACTION IS ENTERED INTO, PROVIDED THE INTEREST OF SUCH OFFICER OR DIRECTOR IS FULLY DISCLOSED TO THE BOARD OF DIRECTORS SUCH TRANSACTIONS IS DULY APPROVED BY THE BOARD OF DIRECTORS NOT SO INTERESTED OR CONNECTED AS BEING IN THE BEST INTERESTS OF THE ORGANIZATION. PAYMENTS TO THE INTERESTED OFFICER OR DIRECTOR ARE REASONABLE AND DO NOT EXCEED FAIR MARKET VALUE. NO INTERESTED OFFICER OR DIRECTOR MAY VOTE OR LOBBY ON THE MATTER OR BE COUNTED IN DETERMINING THE EXISTENCE OF A QUORUM AT THE MEETING AT WHICH SUCH TRANSACTION MAY BE AUTHORIZED. THE MINUTES OF MEETINGS WHICH SUCH VOTES ARE TAKEN SHALL RECORD SUCH DISCLOSURE, ABSTENTION, AND RATIONALE FOR APPROVAL. FORM 990, PART VI, SECTION C, LINE 18 THE ORGANIZATION MAKES ITS FORM 990 AVAILABLE FOR PUBLIC INSPECTION UPON REQUEST AND THROUGH WWW.GUIDESTAR.COM FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST.